Chatham Capital Group
LMAT icon

Chatham Capital Group’s LeMaitre Vascular LMAT Stock Holding History

Chatham Capital Group’s Portfolio LMAT Stock Details LMAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.99M Buy
48,340
+1,795
+4% +$159K 0.51% 62
2026
Q2 		$4.47M Buy
46,545
+2,710
+6% +$278K 0.57% 53
2026
Q1 		$4.79M Sell
43,835
-4,210
-9% -$401K 0.69% 42
2025
Q4 		$3.9M Buy
48,045
+600
+1% +$51.7K 0.55% 59
2025
Q3 		$4.15M Sell
47,445
-2,539
-5% -$227K 0.6% 51
2025
Q2 		$4.15M Sell
49,984
-270
-0.5% -$22.6K 0.63% 47
2025
Q1 		$4.22M Buy
50,254
+1,765
+4% +$164K 0.7% 43
2024
Q4 		$4.47M Sell
48,489
-1,570
-3% -$151K 0.73% 38
2024
Q3 		$4.65M Buy
50,059
+105
+0.2% +$9.1K 0.76% 39
2024
Q2 		$4.11M Buy
49,954
+725
+1% +$53.3K 0.72% 43
2024
Q1 		$3.27M Buy
49,229
+8,770
+22% +$541K 0.6% 54
2023
Q4 		$2.3M Sell
40,459
-394
-1% -$20.6K 0.47% 64
2023
Q3 		$2.23M Sell
40,853
-206
-0.5% -$12.2K 0.5% 64
2023
Q2 		$2.76M Buy
41,059
+2,465
+6% +$150K 0.58% 54
2023
Q1 		$1.99M Buy
38,594
+26
+0.1% +$1.26K 0.44% 76
2022
Q4 		$1.77M Hold
38,568
– – 0.42% 78
2022
Q3 		$1.96M Hold
38,568
– – 0.48% 68
2022
Q2 		$1.76M Buy
38,568
+55
+0.1% +$2.46K 0.4% 75
2022
Q1 		$1.79M Buy
38,513
+566
+1% +$25.3K 0.35% 80
2021
Q4 		$1.91M Buy
37,947
+60
+0.2% +$3.1K 0.34% 76
2021
Q3 		$2.01M Sell
37,887
-436
-1% -$24.6K 0.39% 70
2021
Q2 		$2.34M Buy
38,323
+4
+0% +$212 0.45% 66
2021
Q1 		$1.87M Buy
38,319
+1,142
+3% +$53.5K 0.39% 72
2020
Q4 		$1.51M Sell
37,177
-250
-0.7% -$8.94K 0.34% 80
2020
Q3 		$1.22M Sell
37,427
-178
-0.5% -$5.34K 0.3% 80
2020
Q2 		$993K Buy
37,605
+88
+0.2% +$2.3K 0.26% 88
2020
Q1 		$935K Buy
37,517
+13,023
+53% +$402K 0.28% 85
2019
Q4 		$881K Sell
24,494
-506
-2% -$17.5K 0.22% 101
2019
Q3 		$854K Sell
25,000
-230
-0.9% -$7.35K 0.22% 103
2019
Q2 		$706K Sell
25,230
-414
-2% -$11.5K 0.18% 112
2019
Q1 		$795K Buy
25,644
+184
+0.7% +$4.91K 0.2% 102
2018
Q4 		$602K Buy
+25,460
New +$695K 0.17% 105

Other funds holding LMAT

Congress Asset Management
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return
Copeland Capital Management
Copeland Capital Management Conshohocken, Pennsylvania $4.34B AUM 17.52% 1-Year Est. Return
Vest Financial
Vest Financial Mclean, Virginia $9.5B AUM 22.78% 1-Year Est. Return
Mutual of America Capital Management
Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return
Linden Thomas Advisory Services
Linden Thomas Advisory Services Charlotte, North Carolina $1.26B AUM 37.95% 1-Year Est. Return
Annex Advisory Services
Annex Advisory Services Brookfield, Wisconsin $6.11B AUM 13.75% 1-Year Est. Return
Values First Advisors
Values First Advisors Gray, Tennessee $213M AUM 20.51% 1-Year Est. Return
Illumine Investment Management
Illumine Investment Management Poulsbo, Washington $144M AUM 33.61% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Harbor Capital Advisors
Harbor Capital Advisors Chicago, Illinois $1.48B AUM 30.88% 1-Year Est. Return

Chatham Capital Group's LMAT Position: Q3 2026 in Review

Chatham Capital Group increased its LeMaitre Vascular (LMAT) stake by 3.9% in Q3 2026, buying an estimated $159K and bringing the position to 48,340 shares worth $3.99M. The position accounts for 0.51% of the portfolio, ranked #62.

Chatham Capital Group first reported a position in LMAT in Q4 2018 and has held it in 32 quarters since. The position peaked at $4.79M in Q1 2026. 53 funds tracked by Wall St. Rank hold LMAT as of Q3 2026.

  • Chatham Capital Group held 48,340 shares of LeMaitre Vascular worth $3.99M as of Q3 2026.
  • Chatham Capital Group bought 1,795 LeMaitre Vascular shares in Q3 2026, an estimated $159K.
  • LeMaitre Vascular made up 0.51% of Chatham Capital Group's portfolio in Q3 2026, its #62 holding.
  • Chatham Capital Group first reported a position in LeMaitre Vascular in Q4 2018 and has held it in 32 quarters since.
  • Chatham Capital Group's LeMaitre Vascular position peaked at $4.79M in Q1 2026.
  • 53 funds tracked by Wall St. Rank held LeMaitre Vascular as of Q3 2026.

Based on Chatham Capital Group's 13F filing for Q3 2026, filed 16 Oct 2026.